Kuala Lumpur, September 5, 2025 — Pharmaniaga Bhd is setting its sights on a robust second half of the financial year, buoyed by a resurgence in government hospital orders and ambitious expansion in the insulin and biopharmaceutical segments. Following a subdued second quarter, the group’s outlook is improving markedly.
A downturn in Q2 revenue—down 12% year-over-year—was attributed to a strong first-quarter base, when government hospitals rushed to replenish post-holiday inventories. The group’s medical supplies segment declined 16%, though manufacturing efforts partially offset the dip with a 22% gain. Still, core net profit for H1 rose 19%, reaching RM34 million on the back of stronger overall revenues and improving hospital orders.
Leadership is now optimistic, forecasting volume growth of 10–12% y/y for both Q3 and Q4, even as the latter typically runs softer seasonally. Inventory rationalization is another key strategy, expected to unblock working capital pressures by reducing slow-moving stock.
However, it’s the insulin and biopharmaceutical push that underpins the company’s more transformative ambitions. Pharmaniaga has secured tenders from three teaching hospitals and is targeting four more by 2026. They’re also vying for the Ministry of Health’s national insulin contract, potentially worth up to RM400 million, with supplies expected to begin late 2025 or early FY2026.
Progress in local manufacturing is accelerating. Nine validation batches of human insulin were completed in May 2025, and two new products—an antiviral Entecavir and urology drug Tadalafil—have been rolled out, expanding the group’s presence in therapeutic categories. Business forecasts suggest the biopharma plant could generate RM300–400 million in revenue by 2028, delivering RM18–24 million in net profit—equating to 27–36% of anticipated FY2026 earnings.
Collectively, these developments signal Pharmaniaga’s strategic pivot beyond distribution to more value-added, high-potential manufacturing and R&D—positioning it as a rising star in Malaysia’s nascent biopharma industry.
